Capricor Therapeutics Reports HOPE-3 Publication; FDA BIMO Observation

What Happened

• On July 29, 2026 Capricor Therapeutics announced that The Lancet published the final one‑year results from its HOPE‑3 Phase 3 trial of Deramiocel for Duchenne muscular dystrophy (DMD). The published analysis used the company’s prespecified Statistical Analysis Plan version 3.0 (SAP 3.0).
• During peer review and ongoing dialogue with the FDA, Capricor updated the statistical model for the key secondary endpoint, left ventricular ejection fraction (LVEF). Under the revised model the overall LVEF result is p = 0.09 (a 1.8 percentage‑point treatment difference), versus the previously reported p = 0.04 (2.4 percentage‑point difference). In the prespecified cardiomyopathy subgroup the LVEF result is nominally significant at p = 0.02 (2.8 percentage‑point difference). The primary efficacy endpoint and all other trial data are unchanged.

Key Details

• Publication: The Lancet published final one‑year HOPE‑3 results (announcement dated July 29, 2026).
• LVEF update: overall p changed from 0.04 to 0.09 (treatment difference 2.4 → 1.8 percentage points); cardiomyopathy subgroup p = 0.02 (2.8 pp).
• FDA inspection: Company notified July 4, 2026; FDA BIMO inspection ran July 6–20, 2026 and resulted in one Form FDA 483 observation citing issues around SOPs, documentation, vendor oversight, and audit report timeliness.
• Company stance: Capricor says the observation does not affect HOPE‑3 data integrity and is preparing a formal response.

Why It Matters

• The Lancet publication provides independent, peer‑reviewed visibility and external validation of HOPE‑3 methods and results, an important milestone for investor and regulator assessment.
• The statistical-model update weakens the overall LVEF secondary endpoint from nominal statistical significance (p=0.04) to non‑significance (p=0.09), though a prespecified subgroup remains nominally significant; the primary endpoint and other trial data were not changed. Investors should note this when evaluating the trial’s balance of efficacy signals.
• The FDA Form 483 observation reflects inspection findings on clinical operations; while Capricor says data integrity is unaffected and it will respond to the FDA, the observation is relevant to ongoing BLA review and regulatory interactions. Watch for the company’s FDA response and any follow‑up communications.